HK1100358A1 - 有關治療與胰島素相關的疾病的 及調質 - Google Patents

有關治療與胰島素相關的疾病的 及調質

Info

Publication number
HK1100358A1
HK1100358A1 HK07108497.4A HK07108497A HK1100358A1 HK 1100358 A1 HK1100358 A1 HK 1100358A1 HK 07108497 A HK07108497 A HK 07108497A HK 1100358 A1 HK1100358 A1 HK 1100358A1
Authority
HK
Hong Kong
Prior art keywords
gpr41
modulators
insulin
treatment
related disorders
Prior art date
Application number
HK07108497.4A
Other languages
English (en)
Inventor
James N Leonard
Zhi Liang Chu
Marc A Bruce
P Douglas Boatman
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of HK1100358A1 publication Critical patent/HK1100358A1/zh

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK07108497.4A 2004-11-03 2007-08-06 有關治療與胰島素相關的疾病的 及調質 HK1100358A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62486704P 2004-11-03 2004-11-03
PCT/US2005/039551 WO2006052566A2 (en) 2004-11-03 2005-11-01 Gpr41 and modulators thereof for the treatment of insulin-related disorders

Publications (1)

Publication Number Publication Date
HK1100358A1 true HK1100358A1 (zh) 2007-09-21

Family

ID=36336982

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07108497.4A HK1100358A1 (zh) 2004-11-03 2007-08-06 有關治療與胰島素相關的疾病的 及調質

Country Status (12)

Country Link
US (1) US20080312277A1 (zh)
EP (1) EP1812080B1 (zh)
JP (2) JP5785354B2 (zh)
CN (1) CN101084018B (zh)
AU (1) AU2005305083B2 (zh)
CA (1) CA2584224A1 (zh)
ES (1) ES2498972T3 (zh)
HK (1) HK1100358A1 (zh)
IL (1) IL182574A (zh)
SG (1) SG170642A1 (zh)
TW (1) TWI440460B (zh)
WO (1) WO2006052566A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110010824A (ko) 2003-01-14 2011-02-07 아레나 파마슈티칼스, 인크. 대사 조절제로서의 1,2,3-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
JP4920410B2 (ja) 2003-07-14 2012-04-18 アリーナ ファーマシューティカルズ, インコーポレイテッド 代謝モジュレーターとしての縮合アリールおよびヘテロアリール誘導体ならびに代謝に関連する障害の予防および治療
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
CN102812011A (zh) 2009-11-16 2012-12-05 梅利科技公司 [1,5]-二氮杂环辛间四烯衍生物
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
MX2021011472A (es) 2015-01-06 2022-08-17 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP7105359B2 (ja) 2018-07-13 2022-07-22 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
AU2019366355B2 (en) 2018-10-24 2022-10-13 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN114681447B (zh) * 2020-12-30 2024-05-28 南京盛德瑞尔医药科技有限公司 一种戊酰胺类化合物作为谷氨酸脱氢酶抑制剂的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1255779A2 (en) * 2000-02-18 2002-11-13 Glaxo Group Limited Identification of modulators of gpr41 or gpr42 activity
US20030165501A1 (en) * 2001-02-16 2003-09-04 Genentech, Inc. Treatment involving Dkk-1 or antagonists thereof
MXPA03010903A (es) * 2001-06-07 2004-02-17 Lilly Co Eli Moduladores de receptores activados por el proliferador de peroxisomas.
JP4294497B2 (ja) * 2002-04-16 2009-07-15 協和発酵キリン株式会社 内分泌系細胞株とその利用法
AU2003261935A1 (en) * 2002-09-06 2004-03-29 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
WO2004038421A2 (en) * 2002-10-25 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)

Also Published As

Publication number Publication date
TW200633707A (en) 2006-10-01
EP1812080A2 (en) 2007-08-01
WO2006052566A3 (en) 2006-10-12
CN101084018A (zh) 2007-12-05
EP1812080B1 (en) 2014-07-09
CN101084018B (zh) 2013-12-18
IL182574A (en) 2014-04-30
AU2005305083A1 (en) 2006-05-18
AU2005305083B2 (en) 2012-02-02
JP2008518635A (ja) 2008-06-05
WO2006052566A2 (en) 2006-05-18
IL182574A0 (en) 2008-04-13
JP5785354B2 (ja) 2015-09-30
SG170642A1 (en) 2011-05-30
US20080312277A1 (en) 2008-12-18
CA2584224A1 (en) 2006-05-18
TWI440460B (zh) 2014-06-11
ES2498972T3 (es) 2014-09-26
JP2013082748A (ja) 2013-05-09

Similar Documents

Publication Publication Date Title
IL182574A0 (en) Gpr41 and modulators thereof for the treatment of insulin-related disorders
GB0404693D0 (en) Pharmaceutical preparations for the treatment of ocular surface and other disorders
HK1190084A1 (zh) 用於預防和治療補體相關紊亂的 多肽
IL195819A0 (en) Modulators of metabolism and the treatment of disorders related thereto
IL195851A0 (en) Modulators of metabolism and the treatment of disorders related thereto
EP1926521A4 (en) DEVICES AND METHODS FOR RELEASING THERAPEUTIC SUBSTANCES FOR THE TREATMENT OF SINUSITIS AND OTHER DISORDERS
IL230241A (en) Retinal history and methods of using them to treat visual irregularities
IL179227A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL188204A0 (en) Combination therapy for the treatment of immunoinflammatory disorders
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
PL378108A1 (pl) Leczenie łączone do terapii zapalnych zaburzeń immunologicznych
ZA200705540B (en) Compositions comprising PDE4 modulators and their use for the treatment or prevention of airway inflammation
IL181706A0 (en) The treatment of inflammatory disorders and pain
PL2982372T3 (pl) Środki modulujące stężenie glutaminianu stosowane w leczeniu zaburzeń psychicznych
EP1812077A4 (en) MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING A FIBROSIS-ASSOCIATED DISEASE
IL183656A0 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
EP1814567A4 (en) USE OF MODULATORS OF EPHA2 AND EPHRINA1 FOR TREATING AND PREVENTING INFECTIONS
IL178827A0 (en) Use of reboxetine for the treatment of pain
IL183859A0 (en) Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders
IL198134A (en) A combination of antipsychotic drugs and tetracyclines to treat psychiatric illnesses
IL181777A0 (en) Gpr43 and modulators thereof for the treatment of metabolic-related disorders
ZA200505996B (en) Combination therapy for the treatment of immunoinflammatory disorders
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
GB0513413D0 (en) The treatment of inflammatory disorders and pain
ZA200704412B (en) Indenyl derivatives and use thereof for the treatment of neurological disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181101